title: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.
abstract: We previously described the processing of antibodies to CD74 (the major histocompatibility complex class II-associated invariant chain, Ii), by B-cell lymphoma cell lines. These cells expressed relatively low levels of Ii on the surface, but the molecules were rapidly internalized and replaced by new molecules, so that approximately 8 x 10(6) antibody molecules per cell were taken up per day. We herein report the results of similar studies with other cell types, namely a melanoma, a colon carcinoma, a T-cell lymphoma and B-lymphoblastoid cell lines. The melanoma and the carcinoma were treated with interferon-gamma to induce high levels of the antigen. The T-cell lymphoma, HUT 78, was selected specifically because it was previously reported to lack cell surface Ii, while expressing the molecule intracellularly. However, HUT 78 displayed Ii on the cell surface, as did the other cell lines tested, and catabolism of the antibody was very fast on all of the cell lines. The capacity of four of the cell lines for cumulative antibody uptake was evaluated, using 'residualizing' radiolabels, which are trapped within the cell after catabolism of the antibody to which they were conjugated. A high level of uptake was observed in all cases, although there was significant variation between the cell lines. With melanoma SK-MEL-37, the total LL1 uptake in 24 hr was nearly 10(7) molecules per cell and the average turnover time for Ii on the cell surface was 4 min; with carcinoma HT-29, the total LL1 uptake in 24 hr was approximately 10(6) molecules per cell, and the average turnover time for Ii on the cell surface was 27 min. Based on the cell content of mature class II antigens (alphabeta), these data suggest that a large fraction, or all, of immature class II molecules (alphabetaIi) reach the cell surface before entering the peptide-loading compartment, independent of the particular cell type.
authors.affiliation: Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.
authors.forename: G L
authors.initials: GL
authors.lastname: Ong
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: H J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: M J
authors.initials: MJ
authors.lastname: Mattes
mesh_terms: D000937:Antigen-Antibody Reactions; D015703:Antigens, CD / Q000032:analysis* / Q000378:metabolism; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000949:Histocompatibility Antigens Class II; C045084:invariant chain